Skip to content
value.today

Oncothyreon Inc.

🇺🇸 Seattle, Washington, USABiotechnologyFounded 2007
Total raised
$15 M
1 round on record
Latest round
$15 M
Sep 2010
First round on record
Sep 2010
Today
Private
No later event on record

Funding rounds

1 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Oncothyreon Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2014$23 MIssued in a merger or acquisition$10 to $50 million

Oncothyreon Inc.: Private sale, Aug 2014

Investors in this round

5 investors had bought by the notice of Aug 15, 2014: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 10 investors are named for Oncothyreon Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$23 M of $23 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Diana L. Hausman · Executive Officer
  • Gary L. Christianson · Executive Officer
  • Jay L. Venkatesan · Executive Officer
  • Julia L. Eastland · Executive Officer
  • Robert L. Kirkman · Executive Officer, Director
  • Scott L. Peterson · Executive Officer
  • Christopher L. Henney · Director
  • Daniel W. Spiegelman · Director
  • Richard L. Jackson · Director
  • Ted W. Love · Director
  • W. Vickery Stoughton · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “The securities were issued in connection with a merger, the consideration of which was the exchange of the target's securities for issuer securities.”

Signed by Julia Eastland, Cfo. Source: SEC Form D, newest notice filed Aug 15, 2014. Read the notice at the SEC.

equitySEC
Sep 2010$15 MNo. 1$10 to $50 million

Oncothyreon Inc.: Raise no. 1, Sep 2010

Investors in this round

17 investors had bought by the notice of Oct 6, 2010: 17 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 10 investors are named for Oncothyreon Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$15 M of $28 M offered; $13 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
$1 million to $5 million
Sales commissions
$891,003
Finders' fees
$75,000
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Gary L. Christianson · Executive Officer
  • Julia Marie Eastland · Executive Officer
  • Robert L. Kirkman · Executive Officer, Director
  • Christopher S. Henney · Director
  • Daniel K. Spiegelman · Director
  • Douglas Vickery Williams · Director
  • Richard L. Jackson · Director
  • W. Vickery Stoughton · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • JMP SECURITIES LLC (CRD 22208) · San Francisco, CaliforniaSold in CA, IL, ME, NE, NY
  • ROTH CAPITAL PARTNERS, LLC (CRD 15407) · Newport Beach, CaliforniaSold in CA

Remarks in the notice

  • On fees: “The amounts shown above are the total amounts paid to both of the placement agents.”
  • On the amounts: “The Issuer sold an aggregate of 4,242,870 units to the investors at a price per unit of $3.50. Each unit consisted of one share of common stock and a warrant to purchase 0.75 of a share of common stock at an exercise price of $4.24 per share.”
  • On the use of proceeds: “Proceeds are to be used for general corporate purposes.”

Signed by Robert L. Kirkman, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Oct 6, 2010. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Oncothyreon Inc. chose not to state its revenue in its newest notice of a funding round (Aug 2014).

    SEC Form D · Aug 2014

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Aug 2014

That is all the official record says: Oncothyreon Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

10 named in official filings. Open an investor to see everything it has backed.

Investors in Oncothyreon Inc.
InvestorKindAmountRoundRoleSource
Biotechnology Value Fund II LPFund or asset managernot statednot statedHeld Series A, B and C preferred stock (Form 3, 2015)SEC Form 3
Biotechnology Value Fund L.P.Fund or asset managernot statednot statedHeld Series A, B and C preferred stock (Form 3, 2015)SEC Form 3
Biotechnology Value Trading Fund OS LPFund or asset managernot statednot statedHeld Series A, B and C preferred stock (Form 3, 2015)SEC Form 3
BVF Inc/ilFund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2015)SEC Form 3
BVF Partners L P/ilFund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2015)SEC Form 3
BVF Partners OS Ltd.Fund or asset managernot statednot statedHeld Series A, B and C preferred stock (Form 3, 2015)SEC Form 3
Growth Equity Opportunities IV, LLCOthernot statednot statedHeld Series E preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Nea 15 GP, LLCOthernot statednot statedHeld Series E preferred stock, 10% owner (Form 3, 2017)SEC Form 3
NEA Partners 15, L.P.Fund or asset managernot statednot statedHeld Series E preferred stock, 10% owner (Form 3, 2017)SEC Form 3
New Enterprise Associates 15, L.P.Fund or asset managernot statednot statedHeld Series E preferred stock, 10% owner (Form 3, 2017)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 17 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Oncothyreon Inc.
NameRoleNamed in
Diana L. HausmanExecutive officerAug 2014
Gary L. ChristiansonExecutive officerAug 2014
Jay L. VenkatesanExecutive officerAug 2014
Julia L. EastlandExecutive officerAug 2014
Robert L. KirkmanExecutive officerAug 2014
Scott L. PetersonExecutive officerAug 2014
Julia Marie EastlandExecutive officerOct 2010
Christopher L. HenneyDirectorAug 2014
Daniel W. SpiegelmanDirectorAug 2014
Richard L. JacksonDirectorAug 2014
Robert L. KirkmanDirectorAug 2014
Ted W. LoveDirectorAug 2014
W. Vickery StoughtonDirectorAug 2014
Christopher S. HenneyDirectorOct 2010
Daniel K. SpiegelmanDirectorOct 2010
Douglas Vickery WilliamsDirectorOct 2010